![Yasir Al-Wakeel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yasir Al-Wakeel
Director/Board Member at
MAXCYTE, INC.
Net worth: 104 487 $ as of 2026-08-30
Profile
Yasir Baha Al-Wakeel is CEO-Partner at Flagship Pioneering, LLC since 2025.
Dr. Al-Wakeel is Chief Executive Officer at Vesalius Therapeutics, Inc. since 2025.
Dr. Al-Wakeel is Independent Non-Executive Director at MaxCyte, Inc. since 2021.
Dr. Al-Wakeel is Director at Vicore Pharma Holding AB since 2024.
Dr. Al-Wakeel is Trustee at DRI Healthcare Trust since 2026.
Former roles include Chief Executive Officer at Addition Therapeutics, Inc., Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. in 2017, Research Analyst at Credit Suisse Securities (Europe) Ltd. from 2008 to 2015, Chief Financial Officer at BioNTech US, Inc. from 2017 to 2020, and CFO, CAO & Head-Corporate Development at Kronos Bio, Inc. from 2020 to 2023.
Education includes a doctorate from the University of Oxford in 2005 and a graduate degree from the University of Cambridge in 2001.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MAXCYTE, INC. 0.08% | 2026-06-16 | 80,998 ( 0.08% ) | 104 487 $ | 2026-08-30 |
Yasir Al-Wakeel active positions
| Companies | Position | Start |
|---|---|---|
| MAXCYTE, INC. | Director/Board Member | 2021-06-14 |
| VICORE PHARMA HOLDING AB | Director/Board Member | 2024-05-06 |
| DRI HEALTHCARE TRUST | Director/Board Member | 2026-08-06 |
Flagship Pioneering, Inc.
 Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Private Equity Investor | 2025-08-31 |
Vesalius Therapeutics
 Vesalius Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for common human diseases | Chief Executive Officer | 2025-09-15 |
Former positions of Yasir Al-Wakeel
| Companies | Position | End |
|---|---|---|
| KRONOS BIO, INC. | Director of Finance/CFO | 2023-09-14 |
| NEON THERAPEUTICS, INC. | Director of Finance/CFO | 2020-04-30 |
| MERRIMACK PHARMACEUTICALS | Director of Finance/CFO | 2017-06-30 |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 2015-05-31 |
Training of Yasir Al-Wakeel
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
95
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
BioNTech US, Inc.
 BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
DRI Healthcare Trust
 DRI Healthcare Trust Investment Trusts/Mutual FundsMiscellaneous Operates as a royalty trust | Miscellaneous |
Vesalius Therapeutics
Vesalius Therapeutics BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for common human diseases | Health Technology |
- Stock Market
- Insiders
- Yasir Al-Wakeel
